🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Assessing the Feasibility of Combining Dihydroartemisinin Piperaquine and Primaquine for Malaria Mass Drug Administration in High Endemic Communities in the Eastern Region of Ghana

RecruitingNAAges 3 Months - anyAllNoguchi Memorial Institute for Medical Research
NCT07389057 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

Previous malaria control studies in Ghana have shown that community-wide approaches can substantially reduce malaria infections. In a mass testing, treatment and tracking (MTTT) study, more than 75% of people in target communities were reached, leading to a 24% reduction in asymptomatic malaria after one year. However, rapid diagnostic tests (RDTs) can miss very low-level infections, meaning some infected individuals are not treated and can continue to spread malaria. A pilot malaria mass drug administration (MDA) study using artemether-lumefantrine (AL) in the Eastern Region of Ghana showed a very large reduction (over 95%) in parasite carriage after repeated rounds of treatment. Despite this success, malaria infections later fluctuated, possibly because some parasites remained in mosquitoes and because mature gametocytes-the parasite stage responsible for transmission-are not fully el

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * must be aged 3 months and above and * be resident in the communities for the period of the study, * completed and signed a consent form from the parent or guardian of children below 18 years * Completed and signed assent for 12-17 years old children. * Completed and signed consent for those from age 18 years and above. Exclusion Criteria: * Pregnant women * individual with a life-threatening illness (excluding malaria) * less than 10Kg body weight (or less than 1 year old) * individuals who had experienced adverse effects related to primaquine or * known to be G6PD deficient .
💊

What it tests

  • DHAP
  • Single low dose PQ
📍

Where

1 site
Pokrom sub district
Accra, Ghana
🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy